Johnson & Johnson’s Cancer Growth Story | Business and Finance News

Johnson & Johnson is quietly powering ahead with a powerhouse oncology division, led by Darzalex, whose global sales surged 19% last quarter. Despite spinning off consumer brands, the company is on track for over $100 billion in annual revenue, with $30 billion from cancer treatments — fueling their goal to hit $50 billion in cancer drug sales by 2030. Even as older drugs lose patent protection, high-teens growth in oncology keeps them on course, while their legendary 64-year dividend streak continues. With the global cancer market set to balloon from $280 billion to over $730 billion by 2035, J&J is perfectly positioned to capture massive gains — and investors are still sleeping on this quietly unstoppable giant. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/a6603a712935e4e8